WHO advises against remdesivir for coronavirus treatment | READ DETAILS
chuks oti
Nov 20, 2020
The anti-viral drug remdesivir should not be used to treat Covid-19 patients no matter how severe their illness as it has "no important effect" on survival chances, the World Health Organization said Friday.
Denting hopes in one of the few treatments that had shown some initial promise in severe patients, a WHO Guideline Development Group (GDG) of international experts said there was "no evidence based on currently available data that it does improve patient-important outcomes".
READ ALSO: 'How Osinbajo became chairman of Short People Association of Nigeria' - El-Rufai
The United States, the European Union and other countries have granted temporary approval for the use of remdesivir after initial research showed it may shorten recovery time in some coronavirus patients.
READ ALSO: How 15-Year-Old Was Gang Raped For Five Days In Lagos | READ FULL DETAILS
President Donald Trump was treated with remdesivir among other medicines after he tested positive for Covid-19 in October.
READ ALSO: How a Nigerian Professor's AI System Could Predict Depression Before Symptoms Emerge
Friday's WHO recommendation was based on four international randomised trials among more than 7,000 patients hospitalised with the virus.
READ ALSO: Those Who Stalled Abia's Growth Are Regrouping - Mazi Iroegbu Raises Alarm
Publishing updated treatment guidance in the BMJ medical journal, the panel acknowledged that their recommendation does not mean that remdesivir has no benefit for patients.
READ ALSO: BREAKINGNEWS: BUHARI SET TO RELIEVE MINISTERS, AS HE DEMANDS FOR STATUS REPORT ON APRIL 24
But based on the latest figures, costs and delivery methods, it advised "against administering remdesivir in addition to usual care for the treatment of patients hospitalised with Covid-19, regardless of disease severity".
READ ALSO: How Armed Robber Vomited Razor Blade, Charms After I Touched Him- ACP Danladi
The panel recommended that remdesivir trials continued, however, adding that their advice didn't constitute proof that the treatment couldn't work in Covid-19 cases.
"That's why it's a conditional recommendation. (There may) still be potential small benefit, maybe in a subgroup (of patients)," Janet Diaz, the WHO's head of clinical care, told reporters on Friday.
"Is there a subgroup that may benefit more, such a severe patients versus critical patients"?
READ ALSO: Read The Untold Story Of Minister, Hannatu Musawa's NYSC Saga
Manufacturer Gilead said that remdesivir was recognised as Covid-19 treatment by several official health agencies, including the US National Institutes of Health and Infectious Diseases of America, based on "robust data from several randomised control trials".
READ ALSO: REVEALED: How Common House Rats Can Kill - Shocking Truth Behind Silent Deaths in Nigerian Homes
"We regret that the WHO recommendation do not take this data into account even as the number of new cases globally is increasing considerably," it said.
READ ALSO: Jim Iyke Sparks Outrage: "Doctors Are Trained Not to Heal - Sickness Is Their Business"
'Expensive drug'
The US pharma giant said last month that the drug had boosted 2020 third quarter sales by almost $900 million.
Initially developed as a treatment for the Ebola virus, remdesivir was found in one study published in May to reduce the length of hospital stays for Covid-19 sufferers from 15 to 11 days on average.
READ ALSO: 'How Osinbajo became chairman of Short People Association of Nigeria' - El-Rufai
A subsequent WHO pre-print however found the drug "appeared to have little or no effect" on mortality or length of hospitalisation among more than 11,000 hospitalised patients across 30 countries.
READ ALSO: How 15-Year-Old Was Gang Raped For Five Days In Lagos | READ FULL DETAILS
Peter Horby, professor of Emerging Infectious Diseases and Global Health at Oxford's Nuffield Department of Medicine, said the WHO's recommendation would require a rethink in how hospitalised Covid-19 cases are treated.
READ ALSO: How a Nigerian Professor's AI System Could Predict Depression Before Symptoms Emerge
"Remdesivir is an expensive drug that must be given intravenously for five to ten days, so this recommendation will save money and other healthcare resources," he said.
READ ALSO: Those Who Stalled Abia's Growth Are Regrouping - Mazi Iroegbu Raises Alarm
Credits
Related Stories
How Nonchalant Attitude at Federal Medical Centre Umuahia Is Turning Accident Victims Into Casualties - Shocking Findings Emerge
How a Nigerian Professor's AI System Could Predict Depression Before Symptoms Emerge
Jim Iyke Sparks Outrage: "Doctors Are Trained Not to Heal - Sickness Is Their Business"
Why Nigeria Must Declare a State of Emergency on Malaria - Hon. Amobi Ogah Reveals at National Retreat
'Buhari Died In London Hospital After Promising Nigerians Quality Healthcare' - Activist Adetoun Attacks Late Ex President
REVEALED: How Common House Rats Can Kill - Shocking Truth Behind Silent Deaths in Nigerian Homes
""
— chuks oti